Depression treatment in Eatontown, New Jersey

The clinical name for what most people call "depression" is major depressive disorder (MDD). It's the most-studied mental health condition in psychiatry, with consistent diagnostic criteria across the field. The American Psychiatric Association's current diagnostic manual (DSM-5-TR) defines it by a specific pattern. You need at least five symptoms from a short list, present nearly every day for at least two weeks. At least one of the five has to be depressed mood or loss of interest in things you used to enjoy. The symptoms must cause real impairment — work gets harder, relationships strain, basic self-care erodes — and they can't be explained by another medical condition or substance use.

Three things separate clinical depression from a difficult week or grief. Duration: at least two weeks. Pervasiveness: most of the day, nearly every day, not occasional. Functional impairment: something you used to handle, you can't right now. Grief and depression often look similar at the surface and sometimes co-occur; the diagnostic question is whether the picture fits the criteria above.

We don't diagnose in copy on a website. The criteria below exist so you can match your experience to a recognizable pattern — that's information, not a verdict. The diagnosis itself is made through a clinical interview, usually 60 to 90 minutes long, with a licensed clinician.

Not all depression looks the same. The DSM-5-TR recognizes several distinct patterns, each with different course, triggers, and treatment implications. We see all of these at our clinic.

Major depressive disorder (MDD). The most common form. Episodic by nature — episodes typically last from several weeks to several months and may recur over a lifetime. About half of people who have one episode will have a second; with each subsequent episode, the risk of another rises.

Persistent depressive disorder (PDD), formerly dysthymia. A chronic, lower-grade version that persists for two years or more. The symptoms are usually less acute than MDD but more durable. Many patients with PDD describe it as "this is just how I've always been" — and only realize in treatment that the constant low-energy, low-pleasure baseline isn't normal.

Postpartum depression (PPD). Depression that begins during pregnancy or in the first 12 months after birth. It's distinct from "baby blues" (which resolves in two weeks without treatment) and affects approximately 13% of new parents. We have clinicians with specific perinatal training. See our postpartum depression page for the dedicated detail.

Premenstrual dysphoric disorder (PMDD). Severe mood symptoms tied to the luteal phase of the menstrual cycle, distinct from typical premenstrual syndrome. Treatment may include cycle-tracking, targeted SSRI use, and sometimes hormonal coordination with the patient's OB/GYN.

Seasonal pattern (formerly seasonal affective disorder). A recurrent depression pattern tied to seasonal changes, typically worsening in fall and winter and improving in spring. We address it with a combination of light therapy, standard antidepressant treatment, and behavioral activation.

Treatment-resistant depression (TRD). When two or more standard antidepressants haven't produced adequate response after adequate trials. TRD is where TMS becomes a primary option. See our dedicated treatment-resistant depression page for what changes when standard treatment hasn't worked.

Bipolar depression. Depression that's part of bipolar disorder — a separate condition with different treatment, because antidepressants alone can destabilize bipolar patients. Diagnosis requires distinguishing depressive episodes from any prior manic or hypomanic episodes; we screen for this at every initial evaluation.

Most people who eventually seek depression treatment notice the symptoms for months before they call. That's common, and it isn't a personal failing — depression itself reduces the energy and decision capacity needed to make the call. If anyone in your life has been quietly noticing changes and you're reading this on their behalf, that's a meaningful signal too.

The threshold for seeking care isn't "I meet five DSM criteria." It's simpler. Has your low mood, low energy, or loss of interest lasted more than two weeks? Is it affecting how you function? If yes, talk to someone. A clinician sorts out whether what you're experiencing fits a depression diagnosis, what type, and whether treatment is the right next step. Sometimes the answer is "this is a hard transition, not depression" — that's still useful information.

If you're having thoughts about suicide, harming yourself, or feeling unsafe, call or text 988 immediately. The Suicide and Crisis Lifeline is free, available 24/7, and not the same as our intake line — we're an outpatient clinic, not a 24/7 crisis service. New Jersey residents can also reach the NJ Hopeline at 1-855-654-6735. If you're in immediate physical danger, call 911 or go to your nearest emergency room. Our role begins after a crisis is stabilized, with the slower work of treatment.

Therapy is the first-line evidence-based treatment for mild-to-moderate depression and a core component of treatment for moderate-to-severe presentations. We use evidence-based modalities matched to your specific situation; the most-researched options for depression are below.

Cognitive behavioral therapy (CBT) is the most-studied form of psychotherapy and has the strongest evidence base for depression. A typical course runs 12 to 20 weekly sessions of about 50 minutes each. The work focuses on identifying the thoughts driving how you feel, testing whether those thoughts are accurate, and trying new behaviors between sessions. CBT is structured and time-limited — there's homework, weekly progress measurement (typically with the PHQ-9 standardized tool), and a clear plan for what comes after.

Behavioral activation (BA) is a briefer, action-oriented approach that focuses on getting back into life — scheduling meaningful activities even before the motivation to do them returns. It's particularly effective for patients whose depression has made their world small and whose energy for traditional cognitive work is too low to start there. BA is sometimes used alone (8 to 12 sessions) and sometimes integrated into a longer CBT course.

Interpersonal therapy (IPT) focuses on how depression intersects with relationship transitions, conflicts, and role changes. The work moves the question from "what's wrong with me" to "what's happening between me and the people in my life." IPT is well-suited for depression triggered or sustained by life events: a divorce, a loss, a job change, a child leaving home.

Our team also draws on acceptance and commitment therapy (ACT) and mindfulness-based cognitive therapy (MBCT). MBCT is particularly useful for relapse prevention in patients with multiple prior episodes. Psychodynamic approaches are an option when the situation calls for them.

What to expect in a session. The first visit is a 60- to 90-minute evaluation. Subsequent sessions typically run 50 minutes each. Most patients see meaningful change within 8 to 12 sessions, though some take longer. We measure progress with standardized symptom-rating tools (PHQ-9 most often) every few visits. That way you and your clinician can see whether what you're doing is working. If it isn't, you adjust together.

Telehealth and in-person. Research consistently finds therapy outcomes for depression comparable across telehealth and in-person delivery for most patients. We offer both at our clinic. Some patients prefer the structure of an in-person visit; others find that the lower friction of telehealth keeps them more consistent. Your clinician will share their read on which fits you best.

Antidepressants are the other first-line evidence-based treatment for depression, especially for moderate-to-severe symptoms. The combination of medication plus therapy outperforms either alone for moderate-to-severe depression in most large reviews. For mild depression, therapy alone is often the right starting place.

The first-line classes are SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors). Common SSRIs include sertraline (Zoloft), escitalopram (Lexapro), and fluoxetine (Prozac). Common SNRIs include venlafaxine (Effexor) and duloxetine (Cymbalta). SNRIs are often preferred when depression co-occurs with significant anxiety or chronic pain. Both classes are generally well-tolerated, generic, and inexpensive.

Atypical antidepressants include bupropion (Wellbutrin) — which works on dopamine and norepinephrine rather than serotonin, has no sexual side effects, and can help with low energy and concentration. Bupropion is a reasonable first-line choice for some patients, particularly those who've struggled with SSRI-related sexual side effects in the past or whose depression has prominent low-energy features.

The timeline matters. Antidepressants take time. Most patients notice some change within 2 to 4 weeks, with full response typically appearing at 6 to 8 weeks at an adequate dose. The first two weeks can be the hardest — early side effects (nausea, sleep changes, jitteriness) often appear before therapeutic benefit, which is why some patients quit too early. We coach you through that window so you don't.

Side-effect honesty. SSRIs and SNRIs commonly cause some combination of: gastrointestinal upset early on (usually transient), sexual side effects (often persistent), changes in sleep, and modest weight changes over time. Bupropion can cause increased anxiety, jitteriness, or sleep disruption in sensitive patients. We discuss the trade-offs honestly before starting any medication and check in on side effects at every follow-up.

When to consider switching. Two signals say it's time to revisit the plan. The first: you've been at an adequate dose for 6 to 8 weeks without meaningful response. The second: side effects are limiting your quality of life. Switching to a different antidepressant, augmenting with a second medication, or adding therapy if you're not already in it are all standard next moves.

Don't stop abruptly. Most antidepressants need to be tapered down gradually — stopping suddenly can cause a discontinuation syndrome (flu-like symptoms, sleep disruption, mood changes) that's unpleasant and avoidable. We work the taper into your treatment plan whenever it's time to come off.

For ongoing prescribing and adjustment, see our medication management page; for the initial psychiatric evaluation that determines whether medication is the right call, see psychiatry.

Some patients try two or more antidepressants at adequate doses and durations without enough relief. The clinical name for this pattern is treatment-resistant depression (TRD). It's not rare — roughly a third of patients with major depression don't fully respond to a first or second medication trial. For these patients, transcranial magnetic stimulation (TMS) is FDA-approved as a non-medication treatment.

TMS uses magnetic pulses delivered through a coil placed against the scalp to stimulate the dorsolateral prefrontal cortex — a brain region that's chronically underactive in depression. The treatment is delivered in daily 20- to 40-minute sessions, five days a week, over 4 to 6 weeks. Patients are awake, can drive themselves to and from each session, and can return to work the same day.

Response rates in TRD are typically reported in the 50–60% range across multiple studies and clinical trials, with about a third of TRD patients achieving full remission. Those numbers are honest — TMS is not a magic bullet. But it represents a real option for a population for whom medication trials alone have repeatedly fallen short. For patients who don't respond to TMS, additional approaches (combination medications, augmentation strategies, ketamine/esketamine in specialty settings, ECT) remain on the table.

Side effects are mild. The most common are scalp discomfort during the session and mild headache, both typically transient and resolving within the first week of treatment. Unlike some psychiatric medications, TMS has no systemic side effects — no weight change, no sexual dysfunction, no GI upset. The most important contraindication is metallic implants near the head (some pacemakers, some cochlear implants); we screen for these at the initial consultation.

Insurance coverage. Most commercial plans, Medicare, and NJ FamilyCare cover TMS for treatment-resistant depression with prior authorization. We handle the prior-auth submission and the documentation of prior medication trials. Approval typically takes 3 to 5 business days; we don't start treatment until coverage is confirmed in writing.

If you've already been on two or more antidepressants without enough relief, two pages cover what's next. See our TMS service page for what to expect from TMS itself. See our treatment-resistant depression page for the broader picture of where TMS fits among other options for TRD.

Postpartum depression (PPD) is depression that begins during pregnancy or in the first 12 months after birth. It's distinct from the "baby blues," which is a brief, low-intensity mood disturbance that resolves on its own within the first two weeks. PPD lasts longer, hits harder, and requires the same evidence-based treatment as depression at other points in life — often with additional considerations specific to pregnancy and breastfeeding.

PPD affects approximately 13% of new parents, and likely more since significant under-recognition persists. PPD can present in any parent, including non-birthing partners. It can show up as classic depression symptoms. It can also show up as an unfamiliar pattern: intrusive thoughts about the baby, difficulty bonding, intense irritability, or anxiety overlaid onto everything. The first weeks of new parenthood are exhausting under any circumstances; PPD is when that exhaustion crosses into something that doesn't lift with rest, support, or time.

Treatment for PPD looks like depression treatment broadly — therapy, medication, or a combination. Two things change. First, medication selection during breastfeeding gets extra care. Most modern antidepressants are compatible, but the choice depends on the specific medication and infant factors. Second, we coordinate closely with the patient's OB/GYN or midwife when that's part of the picture. Several of our clinicians have specific perinatal mental health training; tell our intake team this is the focus and we'll match you appropriately.

For the dedicated detail — including the early-warning signs, what makes treatment different from non-perinatal depression, and how we coordinate with obstetric care — see our postpartum depression page.

Depression in adolescents and pre-teens often presents differently than in adults. Irritability is frequently more prominent than overt sadness; school performance can drop without obvious cause; sleep and appetite changes can be misread as typical teenage behavior. Parents often notice the change before the teen names it — and the teen, when finally asked, often confirms it.

Treatment for adolescent depression draws on the same evidence base as for adults. Therapy is the foundation. CBT and IPT-A — an adapted form of IPT for adolescents — are best-established. Medication is added when symptoms warrant it. Fluoxetine and escitalopram are the two SSRIs with the most robust pediatric evidence and are the typical first-line choices when medication is part of the plan.

Some specific risks deserve attention. Major life transitions (a move, a parental separation, a school change, the end of a significant relationship) can precipitate depressive episodes in adolescents that wouldn't surface otherwise. Co-occurring anxiety, ADHD, or substance use is common and changes the treatment plan. Suicide risk in adolescents requires careful screening at every visit; this is non-negotiable in our practice.

For the dedicated parent-facing detail on how depression presents in teens, what to expect from treatment, and how we coordinate with schools and parents, see our teen depression page.